Efficacy of Oxymetazoline on Clinical Symptoms and Cilia Function Following Radiofrequency Turbinate Reduction: A randomized controlled trial

Phase 3

• Conditions: The patients who undergo radiofrequency turbinate reduction for the treatment of inferior turbinate hypertrophy.; Inferior turbinate hypertrophy; Radiofrequency turbinate reduction; Postoperative care; Nasal obstruction

• Registration Number: TCTR20230321012
• Lead Sponsor: /A

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-03-21
• Study Completion: 2024-04-01
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending (Not yet recruiting)
• Sex: All
• Target Recruitment: 52

Inclusion Criteria

The patients 18-year-old or older with chronic rhinitis either allergic rhinitis or non-allergic rhinitis who have failed at least 12-week medication therapy to control nasal obstructive symptom and have standard indication to go on radiofrequency for the turbinate reduction procedure.

Exclusion Criteria

The exclusion criteria include previous turbinate surgery, severe septal deviation and significant septal spur which the septoplasty is considered the concurrent treatment, evidence of rhinosinusitis on clinical history or endoscopy or radiology, nasal valve disorder and autoimmune, infectious or neoplasms diseases such as Wegener disease, cystic fibrosis and lymphoma. The patients who had contraindication for topical decongestant use included cardiovascular diseases, glaucoma, hyperthyroidism, BPH and patients who had depression and were taking an MAOI antidepressant or patients who had history of previous rebound rhinitis.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
OSE score At 1, 2 and 4 weeks NOSE score

Secondary Outcome Measures

Name	Time	Method
VAS score of nasal obstruction At 0, 1, 2 and 4 weeks VAS score of nasal obstruction,Crusting score At 0, 1, 2 and 4 weeks Crusting score ,IT size At 0, 1, 2 and 4 weeks 4-point ordinal scale,Adverse effects (headache, palpitation, burning and dryness in the nose and mouth, rebound rhinitis ) At 0, 1, 2 and 4 weeks Categorical outcomes,Saccharin transportation time At 0 and 4 weeks Continuous outcome